WASHINGTON, D.C. – Harnessing the patient’s own immune system to fight cancer through genetic modification of their own cells is rapidly emerging as a promising treatment option. Although these therapies provide great opportunities, they also pose unique challenges as investigators seek to refine the approach and expand the treatment option to more patients. A panel discussion at the American Association for Cancer Research’s Annual Meeting – featuring the University of Pennsylvania physician-scientist leading the research team whose work has spurred worldwide attention to chimeric antigen receptor (CAR) technologies, and a trial participant whose leukemia remains in remission more than two and a half years after being treated with his own engineered cells – will explore the future of personalized cellular therapies.
WHERE: |
American Association for Cancer Research Annual Meeting
Room 150
Walter E. Washington Convention Center
801 Mt Vernon Pl NW, Washington, DC 20001 |
WHEN: |
Sunday, April 7, 2013
1 to 3 PM EDT |
WHO: |
- Carl June, MD, the Richard W. Vague Professor in Immunotherapy in the Perelman School of Medicine at the University of Pennsylvania and the director of Translational Research in the Abramson Cancer Center
- Douglas Olson, PhD, Penn Medicine modified T cell trial participant
|
Additional information about the trial:
Penn Medicine News Release: Genetically Modified "Serial Killer" T Cells Obliterate Tumors in Patients with Chronic Lymphocytic Leukemia, Penn Researchers Report – August 10, 2011
Penn Medicine News Release: University of Pennsylvania and Novartis Form Alliance to Expand Use of Personalized T Cell Therapy for Cancer Patients – August 6, 2012
Penn Medicine News Release: Leukemia Patients Remain in Remission More Than Two Years After Receiving Genetically Engineered T Cell Therapy – December 8, 2012
T-Cell Therapy Eradicates an Aggressive Leukemia in Two Children – March 22, 2013
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.